Belmore Neidrauer successfully represented Janssen in two summary trials in the Federal Court

Belmore Neidrauer successfully represented Janssen in two summary trials in the Federal Court on infringement issues against Pharmascience and Apotex in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used to treat schizophrenia.

These decisions represent a significant advance in the application of the law relating to induced infringement.